LFTE Nuclear Medicine Link

Feb 4, 2013
Nuclear Medicine on the Internet
Nuclear Medicine updates
Latest in Nuclear Radiology
A conceptual framework for neurotheranostics.
ARRS: 'Neurotheranostics' may be new frontier for nuclear medicine
April 29, 2025
Pet Ct Machine
ARRS: Rib uptake evaluation on F-18 DCFPyL PET/CT presents challenges
April 28, 2025
Patient examples of SPECT/CT and PET/CT RECIP 1.0. (A) SPECT and PET maximum-intensity projection (MIP) images in 74-year-old man with mCRPC. Serum PSA level at baseline was 449 ng/mL and slightly increased to 525 ng/mL after two cycles of Lu-177 PSMA. Eastern Cooperative Oncology Group (ECOG) score was 2 at baseline and increased to 3 after 2 cycles. The patient was classified by readers as RECIP-progressive disease on both SPECT and PET. Overall survival was 4.7 months. Two cycles of Lu-177 PSMA were administered. (B) SPECT and PET MIP images in 74-year-old man with mCRPC. Serum PSA level was 231 ng/mL at baseline and decreased to 12.5 ng/mL after 2 cycles of Lu-177 PSMA. ECOG score was less than 2 at baseline and after 2 cycles of Lu-177 PSMA. The patient was classified by readers as RECIP-partial response on both SPECT and PET. Overall survival was 14.3 months. Four cycles of Lu-177 PSMA were administered.
SPECT/CT predicts overall survival in Pluvicto patients
April 25, 2025
Brain MRI and F-18 FDG brain and whole-body PET/CT images. (A) No obvious abnormalities were found in axial and sagittal slices from T2-weighted MR images. (B) Whole cerebellar cortex had diffuse F-18 FDG hypermetabolism in PET/CT brain images, with SUVmax of 25.91. (C and D) Whole-body F-18 FDG-PET/CT showing distended bladder. TLG = total lesion glycolysis; MTV = metabolic tumor volume. Image and caption courtesy of the Journal of Nuclear Medicine.
PET/CT visualizes extremely rare brain inflammation
March 27, 2025
More in Nuclear Radiology
ARRS: 'Neurotheranostics' may be new frontier for nuclear medicine
By Will Morton
Advances in brain PET imaging combined with new treatments for Alzheimer’s have given rise to a new concept of "neurotheranostics."
April 29, 2025
A conceptual framework for neurotheranostics.
ARRS: Rib uptake evaluation on F-18 DCFPyL PET/CT presents challenges
By Maryam Payne
Evaluating increased rib uptake on F-18 DCFPyL PET/CT in prostate cancer patients may lead to false positives.
April 28, 2025
Pet Ct Machine
SPECT/CT predicts overall survival in Pluvicto patients
By Will Morton
New evidence supports using SPECT/CT scans along with serum PSA levels to evaluate early patient responses to Pluvicto treatment.
April 25, 2025
Patient examples of SPECT/CT and PET/CT RECIP 1.0. (A) SPECT and PET maximum-intensity projection (MIP) images in 74-year-old man with mCRPC. Serum PSA level at baseline was 449 ng/mL and slightly increased to 525 ng/mL after two cycles of Lu-177 PSMA. Eastern Cooperative Oncology Group (ECOG) score was 2 at baseline and increased to 3 after 2 cycles. The patient was classified by readers as RECIP-progressive disease on both SPECT and PET. Overall survival was 4.7 months. Two cycles of Lu-177 PSMA were administered. (B) SPECT and PET MIP images in 74-year-old man with mCRPC. Serum PSA level was 231 ng/mL at baseline and decreased to 12.5 ng/mL after 2 cycles of Lu-177 PSMA. ECOG score was less than 2 at baseline and after 2 cycles of Lu-177 PSMA. The patient was classified by readers as RECIP-partial response on both SPECT and PET. Overall survival was 14.3 months. Four cycles of Lu-177 PSMA were administered.
PET/CT visualizes extremely rare brain inflammation
By Will Morton
An F-18 FDG-PET/CT scan proved crucial in identifying an ultrarare case of brain inflammation in a patient due to the flu.
March 27, 2025
Brain MRI and F-18 FDG brain and whole-body PET/CT images. (A) No obvious abnormalities were found in axial and sagittal slices from T2-weighted MR images. (B) Whole cerebellar cortex had diffuse F-18 FDG hypermetabolism in PET/CT brain images, with SUVmax of 25.91. (C and D) Whole-body F-18 FDG-PET/CT showing distended bladder. TLG = total lesion glycolysis; MTV = metabolic tumor volume. Image and caption courtesy of the Journal of Nuclear Medicine.
Hermes Medical Solutions updates dosimetry software
By AuntMinnie.com staff writers
Hermes Medical Solutions has updated and released its Hermia Voxel Dosimetry software.
October 15, 2024
Ame 2018 12 11 00 02 7009 Atom Nuclear Lab 400
The rise of theranostics: Part 5 -- Advice from center administrators
By Liz Carey
Want to launch theranostics at your hospital and cancer center? An SNMMI 2024 session provided key planning steps.
July 12, 2024
Nuclear medicine technologist and theranostics practice administrator Dmitry Beyder (left) and Vikas Prasad, MD, PhD (right), lead the theranostics center at Barnes-Jewish Hospital/Washington University in Saint Louis, MO. Image courtesy of Washington University.
The rise of theranostics: Part 3 -- What is a theranostics center?
By Liz Carey
For this third in a series covering the rise of theranostics, AuntMinnie.com asked four doctors of theranostics to discuss the spectrum of freestanding theranostics center development.
June 3, 2024
Part3 Riseof Thernaostics Cover
Evergreen Theragnostics raises $26M
By AuntMinnie.com staff writers
Evergreen Theragnostics has completed a $26 million capital raise through its existing shareholders and new backers Petrichor and LIFTT.
April 19, 2024
Money Bills 400
IMV: Nuclear medicine procedure volumes decrease
By Davin Korstjens
Total nuclear medicine patient study volumes decreased between 2021 and 2023, according to a newly published IMV 2024 Nuclear Medicine Market Outlook Report.
April 15, 2024
Scientist Atom Molecule
Life Molecular Imaging, Sofie add Neuraceq availability out of Ohio
By AuntMinnie.com staff writers
Life Molecular Imaging and Sofie Biosciences have begun offering the Neuraceq PET radiotracer produced at Sofie's radiopharmaceutical manufacturing site in Cleveland, Ohio.
April 5, 2024
Brain Puzzle Dementia Social
RSNA calls out toxicity concerns with theranostics
By AuntMinnie.com staff writers
RSNA experts recommend proceeding conservatively with theranostic treatments until dose limits to normal organs are established.
March 22, 2024
Yellow Caution Tape Social
Clarity reports on third cohort in copper theranostic trial
By AuntMinnie.com staff writers
Australian radiopharmaceutical developer Clarity Pharmaceuticals has completed the third cohort in the theranostic SECuRE trial.
March 15, 2024
Prostate Cancer 400
Page 1 of 80
Next Page